Cellectis S.A. (CMVLF)
USD 1.25
(0.0%)
USD 1.25
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -43.81 Million USD | -195.12% |
| 2022 | -14.84 Million USD | 82.3% |
| 2021 | -83.89 Million USD | 46.54% |
| 2020 | -156.94 Million USD | 49.91% |
| 2019 | -313.3 Million USD | 30.46% |
| 2018 | -450.53 Million USD | -51.72% |
| 2017 | -296.94 Million USD | -2.84% |
| 2016 | -288.74 Million USD | 15.42% |
| 2015 | -341.38 Million USD | -158.36% |
| 2014 | -132.13 Million USD | -2639.43% |
| 2013 | -4.82 Million USD | 79.18% |
| 2012 | -23.16 Million USD | -263.73% |
| 2011 | 14.14 Million USD | 146.91% |
| 2010 | -30.16 Million USD | 51.9% |
| 2009 | -62.7 Million USD | -65.18% |
| 2008 | -37.96 Million USD | -3.34% |
| 2007 | -36.73 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -38.83 Million USD | -105.53% |
| 2024 Q1 | -18.89 Million USD | 56.88% |
| 2023 Q4 | -43.81 Million USD | -364.1% |
| 2023 FY | -43.81 Million USD | -195.12% |
| 2023 Q2 | 14.37 Million USD | 252.91% |
| 2023 Q3 | 16.59 Million USD | 15.41% |
| 2023 Q1 | -9.4 Million USD | 36.68% |
| 2022 Q4 | -14.84 Million USD | 33.62% |
| 2022 Q3 | -22.36 Million USD | 36.97% |
| 2022 FY | -14.84 Million USD | 82.3% |
| 2022 Q1 | -56.12 Million USD | 33.11% |
| 2022 Q2 | -35.48 Million USD | 36.77% |
| 2021 Q1 | -103.75 Million USD | 33.89% |
| 2021 Q4 | -83.89 Million USD | 21.9% |
| 2021 Q2 | -142.63 Million USD | -37.48% |
| 2021 Q3 | -107.42 Million USD | 24.69% |
| 2021 FY | -83.89 Million USD | 46.54% |
| 2020 Q1 | -237.09 Million USD | 24.32% |
| 2020 FY | -156.94 Million USD | 49.91% |
| 2020 Q3 | -157.78 Million USD | 14.91% |
| 2020 Q4 | -156.94 Million USD | 0.53% |
| 2020 Q2 | -185.42 Million USD | 21.79% |
| 2019 Q4 | -313.3 Million USD | -6.2% |
| 2019 Q2 | -349.15 Million USD | 9.5% |
| 2019 Q1 | -385.8 Million USD | 14.37% |
| 2019 FY | -313.3 Million USD | 30.46% |
| 2019 Q3 | -295.02 Million USD | 15.5% |
| 2018 Q3 | -475.28 Million USD | -1.08% |
| 2018 Q2 | -470.21 Million USD | -95.1% |
| 2018 Q1 | -241.01 Million USD | 18.84% |
| 2018 FY | -450.53 Million USD | -51.72% |
| 2018 Q4 | -450.53 Million USD | 5.21% |
| 2017 Q4 | -296.94 Million USD | -12.56% |
| 2017 Q2 | -231.73 Million USD | 2.13% |
| 2017 Q1 | -236.77 Million USD | 18.0% |
| 2017 FY | -296.94 Million USD | -2.84% |
| 2017 Q3 | -263.81 Million USD | -13.84% |
| 2016 Q3 | -206.81 Million USD | -3.42% |
| 2016 FY | -288.74 Million USD | 15.42% |
| 2016 Q2 | -199.98 Million USD | 6.36% |
| 2016 Q4 | -288.74 Million USD | -39.62% |
| 2016 Q1 | -213.56 Million USD | 37.44% |
| 2015 Q3 | -310.89 Million USD | 1.28% |
| 2015 Q4 | -341.38 Million USD | -9.81% |
| 2015 Q2 | -314.91 Million USD | -146.72% |
| 2015 FY | -341.38 Million USD | -158.36% |
| 2015 Q1 | -127.63 Million USD | 3.4% |
| 2014 Q3 | -137.47 Million USD | -521.62% |
| 2014 Q4 | -132.13 Million USD | 3.88% |
| 2014 Q2 | -22.11 Million USD | 3.49% |
| 2014 Q1 | -22.91 Million USD | -375.07% |
| 2014 FY | -132.13 Million USD | -2639.43% |
| 2013 Q2 | -11.15 Million USD | -53.68% |
| 2013 Q1 | -7.25 Million USD | 68.68% |
| 2013 Q4 | -4.82 Million USD | 11.66% |
| 2013 Q3 | -5.45 Million USD | 51.04% |
| 2013 FY | -4.82 Million USD | 79.18% |
| 2012 FY | -23.16 Million USD | -263.73% |
| 2012 Q2 | -29.74 Million USD | 0.0% |
| 2012 Q4 | -23.16 Million USD | 0.0% |
| 2011 FY | 14.14 Million USD | 146.91% |
| 2011 Q4 | 14.14 Million USD | 0.0% |
| 2010 FY | -30.16 Million USD | 51.9% |
| 2010 Q4 | -30.16 Million USD | 0.0% |
| 2010 Q2 | -46.5 Million USD | 0.0% |
| 2009 FY | -62.7 Million USD | -65.18% |
| 2009 Q2 | -37.98 Million USD | 0.0% |
| 2009 Q4 | -62.7 Million USD | 0.0% |
| 2008 Q4 | -37.96 Million USD | 0.0% |
| 2008 FY | -37.96 Million USD | -3.34% |
| 2007 FY | -36.73 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -3344852.137% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 875.779% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 202.397% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -17454.232% |
| Rebus Holdings, Inc. | 305 Thousand USD | 14466.844% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -595.039% |
| Qrons Inc. | 351.42 Thousand USD | 12568.841% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 7140.715% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 200.886% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -214614.195% |
| Skye Bioscience, Inc. | -5.72 Million USD | -665.878% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 377.986% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 1164.075% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 11004.313% |
| SQZ Biotechnologies Company | -36.23 Million USD | -20.92% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 2054.252% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 4826.007% |
| Mesoblast Limited | 55.85 Million USD | 178.447% |
| Marizyme, Inc. | 18.56 Million USD | 335.978% |
| Genus plc | 190.6 Million USD | 122.99% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 2059.846% |
| Pharming Group N.V. | 109.8 Million USD | 139.906% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 5193.79% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 3709.795% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 6543.952% |
| ContraFect Corporation | -6.02 Million USD | -627.164% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 32645.453% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 3892.433% |
| IMV Inc. | 7.67 Million USD | 671.263% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 896.432% |
| MultiCell Technologies, Inc. | 90.04 USD | 48666107.33% |
| ONE Bio Corp. | 9.04 Million USD | 584.72% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -5870.053% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 438.474% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 3303.202% |
| Q BioMed Inc. | 4.06 Million USD | 1179.28% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 243.415% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 4448.336% |
| Biomind Labs Inc. | 711.4 Thousand USD | 6259.509% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 172.373% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 2291.61% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 442.159% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 12281.722% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 31443.075% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 220661.096% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 2089.975% |
| GB Sciences, Inc. | 1.74 Million USD | 2607.782% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -23742.075% |
| HST Global, Inc. | 96.79 Thousand USD | 45370.704% |
| CSL Limited | 10.52 Billion USD | 100.416% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 21348.914% |
| Halberd Corporation | 144.72 Thousand USD | 30378.172% |
| Enzolytics Inc. | 981.65 Thousand USD | 4563.771% |
| Agentix Corp. | 37.63 Thousand USD | 116543.552% |
| Resverlogix Corp. | 6.45 Million USD | 779.257% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -6410.116% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 97.84% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 6.792% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 719.701% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 1717.759% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -395.694% |
| AVAX Technologies, Inc. | -5.9 Million USD | -642.289% |
| Zenith Capital Corp. | 10.06 Thousand USD | 435502.156% |
| Genscript Biotech Corporation | -1.06 Billion USD | 95.871% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 21962.214% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 1936.473% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 26736.155% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -239112.103% |
| Kadimastem Ltd | -253.1 Thousand USD | -17212.733% |
| Helix BioMedix, Inc. | -2.57 Million USD | -1604.993% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 316.112% |
| BioStem Technologies, Inc. | 4.47 Million USD | 1079.847% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 21872.92% |
| LadRx Corporation | -2.03 Million USD | -2051.708% |
| Cell Source, Inc. | 9.23 Million USD | 574.643% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 6998.796% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 6998.796% |
| NovAccess Global Inc. | 2.17 Million USD | 2111.456% |
| Affymax, Inc. | -5.59 Million USD | -682.899% |
| Itoco Inc. | 228.3 Thousand USD | 19293.129% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 32322.366% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 983.98% |
| Mobile Lads Corp. | 484.23 Thousand USD | 9149.149% |
| CytoDyn Inc. | 20.26 Million USD | 316.261% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -6772523.338% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -472680.163% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 668.633% |
| SYBLEU INC | 473.71 Thousand USD | 9350.069% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 1083.142% |
| International Stem Cell Corporation | 2.59 Million USD | 1791.848% |
| Bioxytran, Inc. | 1.89 Million USD | 2407.575% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 70307.926% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 2109.211% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 1376.03% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 612.322% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 5771.56% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -3405.51% |
| Neutra Corp. | 52.18 Thousand USD | 84065.112% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -1660.501% |
| PureTech Health plc | -167.19 Million USD | 73.792% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -17791.973% |
| IXICO plc | -4.44 Million USD | -885.893% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 431.484% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 179.887% |
| CSL Limited | 10.52 Billion USD | 100.416% |